Optimizing Dosage Selection Strategies in Oncology – ASCO

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

“A new report calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the ‘maximum tolerated dose’ (MTD) may be outdated, harmful to patients, and ill-suited for modern cancer therapies.

‘The Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology,’ a new report published July 24 in the Journal of Clinical Oncology, is the result of a joint collaboration between the American Society of Clinical Oncology and the Food and Drug Administration. It identifies critical shortcomings in the current MTD-centric paradigm and outlines five guiding principles for optimizing cancer therapy dosage moving forward.

Read the full report.”